Novaremed Enters Into an Exclusive Option and License Agreement With NeuroFront for the Non-opioid Neuropathic Pain Treatment, NRD.E1, for Greater China and Singapore
21.7.2022 10:58:00 EEST | Business Wire | Press release
Novaremed AG and NeuroFront Therapeutics (Hong Kong) Limited jointly announce the signing of an exclusive collaboration and commercialization agreement for Novaremed’s innovative non-opioid investigational drug, NRD.E1, being developed for the treatment of diabetes-related neuropathic pain and other neuropathic pain indications. Under the terms of the agreement, Novaremed is eligible to receive from NeuroFront over USD 130 million in option and exercise fees as well as development, regulatory and sales milestone payments plus royalties on net sales.
Under the terms of the agreement, Novaremed will grant NeuroFront an exclusive option to obtain exclusive development, commercialization and manufacturing rights to NRD.E1, Novaremed’s first-in-class, innovative non-opioid investigational drug candidate for the treatment of neuropathic pain. The agreement allows NeuroFront to develop and commercialize NRD.E1 as treatment of painful diabetic peripheral neuropathy (PDPN) and any other neuropathic pain indications in the Greater China territory (including Mainland China, Hong Kong, Macau, and Taiwan) and Singapore.
NeuroFront has the right to exercise its license option at its discretion, but no later than upon completion of the Phase 2b trial of NRD.E1 in PDPN, which will start patient enrollment in coming weeks.
In case NeuroFront successfully develops and registers NRD.E1 in additional neuropathic pain indications in the licensed territory, Novaremed is also eligible to receive additional development and regulatory milestone payments for each additional indication.
“We are very delighted collaborating with NeuroFront to advance our non-opioid neuropathic pain treatment for patients suffering from PDPN and other neuropathic pain indications in China. Currently, approved medications for PDPN provide inadequate pain relief and are associated with many intolerable side effects. Based on both preclinical and clinical data, we believe NRD.E1 has the potential to offer unique benefits and revolutionize the way PDPN is treated,” said Isaac Kobrin, MD, Executive Chairman of Novaremed. “NeuroFront’s development and commercial expertise and its focus on innovative CNS drugs is complementary to our expertise and an ideal fit for Novaremed.”
“There are up to 19 million patients suffering from PDPN in China, but no new innovative drug has been introduced in the market for more than 15 years. There exists a significant unmet medical need and hence a great opportunity for NRD.E1, a first-in-class, novel treatment that has already demonstrated clinical effectiveness in a Phase 2a clinical trial and subsequently received US FDA Fast Track Designation and NIH sponsorship for its Phase 2b trial,” said June Yan, CEO of NeuroFront. “NeuroFront is very excited to partner with Novaremed to change the lives of many PDPN patients in Greater China and Singapore.”
This partnership and the transaction were facilitated with the assistance of Cukierman and Company Investment House.
About NRD.E1 and the treatment of chronic pain
NRD.E1 is an orally active small molecule with a novel mechanism of action by modulating Lyn kinase and has patent protection until 2040. NRD.E1 is Novaremed’s lead drug candidate currently being developed to treat painful diabetic peripheral neuropathy (PDPN). Novaremed successfully completed three Phase 1 studies [1] and one double-blind, placebo-controlled Phase 2a dose-finding proof-of-concept study [2] in which NRD.E1 showed a clinically relevant reduction in patient-reported pain (measured as an improvement in mean neuropathic pain score) and was very well tolerated at all doses tested.
On the basis of these results, NRD.E1 has been granted Fast Track Designation by the US FDA and was selected by the National Institutes of Health (NIH) in the US as the only oral agent to be included in the NIH-HEAL (Help End Long-term Addiction) program. The NIH will sponsor and execute a 12-week, double-blind, placebo-controlled Phase 2b study in patients with moderate to severe PDPN in the US. Recruitment into this clinical trial will start in coming weeks.
About NeuroFront
NeuroFront is a China-based clinical stage neuroscience biotech company with a focus on developing and commercializing innovative neuroscience therapies to address unmet needs and improve patients' lives in China and Asia. NeuroFront was established by top-tier life sciences investors, including Nan Fung Life Sciences and Pivotal bioVenture Partners China, and is led by an elite team of neuroscience industry veterans with substantial and compelling expertise in China and globally in both R&D and the commercialization of CNS products. NeuroFront is building a portfolio of innovative, transformative CNS therapies that treat migraine, painful diabetic peripheral neuropathy, depression, ADHD, and other CNS diseases with high unmet medical needs. For more information: www.neurofrontrx.com.
About Novaremed
Novaremed AG, a privately held clinical-stage biopharmaceutical company, is developing a pipeline of innovative medications for chronic pain management to address the high unmet medical need for better pain relief and as an alternative to opioids. Its lead product is NRD.E1, an orally active non-opioid small molecule with a novel mechanism of action, has FDA Fast Track Designation and IND-approval to proceed with a Phase 2b clinical trial for the treatment of painful diabetic peripheral neuropathy (PDPN). The earlier stage pipeline addressing chronic neuropathic pain includes the development candidates MP-101 (Phase 2 stage), and MP-103 (preclinical stage), targeting the unmet medical need of prevention and treatment of chemotherapy-induced peripheral neuropathy (CIPN). Novaremed Ltd (Israel) and Metys Pharmaceuticals AG (Switzerland) are fully owned subsidiaries of Novaremed AG, domiciled in Basel (Switzerland). For more information: www.novaremed.com.
References
[1] Tiecke E., Rainisio M., Guentert T., Müller S., Hochman L., Kaplan E., Mangialaio S. (2022). First-in-human single-ascending-dose, multiple-dose and food interaction studies of NRD.E1, an innovative non-opioid therapy for painful diabetic peripheral neuropathy. Clinical Pharmacology in Drug Development (CPDD). (https://accp1.onlinelibrary.wiley.com/doi/10.1002/cpdd.1103)
[2] Tiecke E., Rainisio M., Eisenberg E., Wainstein J., Kaplan E., Silverberg M., Hochman L., Mangialaio S. (2022). NRD.E1, an innovative non-opioid therapy for painful diabetic peripheral neuropathy – a randomized proof of concept study. European Journal of Pain. (https://onlinelibrary.wiley.com/doi/10.1002/ejp.1989)
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220721005391/en/
Contact information
Contact for Novaremed
Mark Altmeyer, Executive Member of the Board
mark.altmeyer@novaremed.com
Contact for NeuroFront
Bin Yao, VP of Operations and Commercialization
bin.yao@neurofrontrx.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Venture Global Launches First Advertising Campaign: “Unstoppable Energy”23.3.2026 12:30:00 EET | Press release
Today, Venture Global, Inc. (NYSE: VG) is launching its first national advertising campaign – “Unstoppable Energy”. The seven-figure, year-long campaign includes national and local broadcast television spots, as well as out-of-home, print, and digital ad placements. The company is proud to have Academy-Award winner Billy Bob Thornton as the campaign voiceover. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323692879/en/ “Venture Global is excited to unveil our very first national advertising campaign, featuring the accomplished Billy Bob Thornton as its voice,” said Venture Global CEO Mike Sabel. “The Unstoppable Energy campaign portrays the roll-up-your-sleeves tenacity and innovation that drives our company every day. We are proud to introduce the ethos and story of the Venture Global brand across the U.S. as we grow into one of the largest liquefied natural gas (LNG) exporters in the world.” About Venture Global Ventur
Venture Global and Vitol Announce New LNG Purchase Agreement23.3.2026 12:00:00 EET | Press release
Today, Venture Global, Inc. (NYSE: VG) and Vitol announced the execution of a new, binding agreement for the purchase of approximately 1.5 million tonnes per annum (MTPA) of U.S. liquefied natural gas (LNG) from Venture Global for five years commencing in 2026, to be supplied from Venture Global’s portfolio. “Global demand for flexible, reliable U.S. LNG is rapidly growing, and Venture Global is proud to work with premier LNG trading companies like Vitol to provide this critical supply to the market,” said Venture Global CEO Mike Sabel. “Thanks to our innovative model, we have the ability to provide our customers with short, medium, and long-term LNG supply, and this agreement is another important step in diversifying the tenor of our LNG portfolio.” “Vitol is delighted to be working with Venture Global, a leading producer and supplier of LNG to world markets,” said Pablo Galante Escobar, Global Head of LNG at Vitol. “LNG is important to many economies worldwide. Through this transacti
RSA Launches ID Plus Sovereign Deployment: The Next Level of High Assurance Identity Security23.3.2026 12:00:00 EET | Press release
Today at RSAC Conference 2026, RSA, the security-first identity leader, announced the launch of RSA® ID Plus Sovereign Deployment, a groundbreaking evolution in high assurance identity solutions designed to meet the needs of organizations that must maintain constant availability, meet policy and data sovereignty laws, and defend themselves from advanced, persistent threats. RSA ID Plus Sovereign Deployment is the next evolution in RSA® ID Plus, the market’s most secure identity and access management (IAM) security platform featuring complete multi-factor authentication (MFA), SSO, and access capabilities. RSA ID Plus Sovereign Deployment features a new “deploy anywhere” capability that allows government agencies, financial services, critical infrastructure, and healthcare organizations to modernize their identity infrastructure while still maintaining the highest standards in security, availability, and regulatory compliance. Unlike other vendors that offer limited technology or reduce
Klarna Expands Its Partnership With H&M in Romania and Hungary23.3.2026 11:46:00 EET | Press release
Klarna, a global digital bank and provider of flexible payment solutions, and H&M, one of the world's largest fashion retailers, announce the expansion of their partnership in Romania and Hungary as a strategic step that strengthens the long-standing global collaboration between the two companies. Klarna is now available as a payment method for H&M customers in both markets, offering a smooth, more predictable checkout experience and payment options tailored to the different needs of shoppers. The integration of Klarna into H&M online stores is an important feature for customers, who will thus be able to access interest-free flexible payment options. More flexibility at checkout By integrating Klarna into the payment process, H&M customers shopping online in Romania and Hungary can benefit from a full range of deferred payment options, flexible solutions with no interest or fees if payment is made on time. Depending on eligibility, customers can choose between paying in full with Klarn
Recyclable Packaging and Responsible Water Management: Barilla’s Commitment to a More Sustainable Future23.3.2026 11:30:00 EET | Press release
With 99.8% of the packaging designed to be recyclable and a 45% increase in water recycled and reused in 2024 compared to 2022, Barilla continues to strengthen its commitment to the responsible management of resources. The company is reaffirming this commitment on the occasion of Global Recycling Day (March 18) and World Water Day (March 22), two moments that highlight the importance of increasingly sustainable production models – from efficient water management to the design of more circular packaging solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260320294356/en/ Barilla Group's Rubbiano Plant (PR) WATER AS A STRATEGIC RESOURCE TO PROTECT A fundamental resource for pasta production and for the balance of ecosystems, water is a central element in Barilla’s management of its operations. The company works to progressively reduce water consumption in its production processes, promoting the responsible use of this re
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom